The peptide research and studies page covers the evidence base that informs monitoring recommendations
This is an industry first
There are several types of GLP medications that engage different types of glucagon receptors, giving them different effects in different people: Single receptor agonists (GLP-1 only): Ozempic, Wegovy, Saxenda Dual receptor agonists (GLP-1 + GIP): Mounjaro, Zepbound Triple receptor agonists (GLP-1 + GIP + glucagon): in development early studies show even greater metabolic effects These medications are changing how we are able to ameliorate obesity, food addiction, insulin resistance, and cardiometabolic risks
Like all of the plans you can use in the BodySite patient management platform, the content is dripped out to the patient as often as every day, with just enough content and tasks for engagement, but not so much that its overwhelming
Eat smaller, more frequent meals to reduce intestinal stress